Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 17/20 | 0.96 |
| ▸ | ACHE | P22303 | 13/20 | 0.96 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.79 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.68 |
| ▸ | TSHR | P16473 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21866762 | 0.98 | HTR4 (1.00) | HTR4ACHESIGMAR1MEN1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL17709646 | 0.97 | ACHE (1.00) | HTR4ACHESIGMAR1MEN1ALDH1A1 | |
| SCHEMBL17709634 | 0.91 | HTR4 (1.00) | HTR4ACHESIGMAR1MEN1ALDH1A1 | |
| SCHEMBL17709620 | 0.89 | HTR4 (1.00) | HTR4ACHESIGMAR1MEN1ALDH1A1 | |
| SCHEMBL17709615 | 0.89 | HTR4 (1.00) | HTR4ACHESIGMAR1MEN1ALDH1A1 | |
| SCHEMBL7350324 | 0.89 | HTR4 (1.00) | HTR4ACHESIGMAR1MEN1ALDH1A1 | |
| SCHEMBL17709636 | 0.89 | ACHE (1.00) | HTR4ACHESIGMAR1 | |
| SCHEMBL17709631 | 0.89 | ACHE (1.00) | HTR4ACHESIGMAR1 | |
| SCHEMBL30139057 | 0.89 | ACHE (1.00) | HTR4ACHESIGMAR1 | |
| SCHEMBL7354794 | 0.84 | HTR4 (1.00) | HTR4ACHESIGMAR1MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9663465-B2 | Acetylcholinesterase inhibitors and promnesiant serotonin 5-HT4 receptor agonists, their methods of preparation and the pharmaceutical compositions containing the same | UNIVERSITE DE CAEN (FR) | 2017-05-30 | — | — | US | disclosed |
| US-20160122300-A1 | ACETYLCHOLINESTERASE INHIBITOR COMPOUNDS AND 5HT4 SEROTONERGIC RECEPTOR AGONISTS, WITH PROMNSIA EFFECT, METHODS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | UNIVERSITE DE CAEN (FR) | 2016-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160122300-A1 | ACETYLCHOLINESTERASE INHIBITOR COMPOUNDS AND 5HT4 SEROTONERGIC RECEPTOR AGONISTS, WITH PROMNSIA EFFECT, METHODS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | HTR4, CHRNA4, CHRNB4 | HTR4 1/4885ACHE 6/4885SIGMAR1 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.